GlassScriptPhysician profile
Johnnie A Westerfield
NPI 1558656553
$6,528.57
in general payments reported to CMS, 2019-2025
30 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,145 · 2022: $1,131 · 2023: $1,877 · 2024: $376.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,252.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $2,331.77 | 2021-2024 | |
| Inspire Medical Systems, INC. | $541.13 | 2021-2023 | Inspire |
| Harmony Biosciences LLC | $415.62 | 2022-2024 | Wakix |
| Abbott Laboratories | $378.47 | 2021 | |
| Merck Sharp & Dohme LLC | $358.66 | 2021-2023 | Belsomra |
| Novo Nordisk INC | $301.26 | 2021 | |
| Axsome Therapeutics, INC. | $294.92 | 2023-2024 | Sunosi |
| Sanofi-Aventis U.S. LLC | $224.32 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $198.32 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.31 | 2021 | |
| 3b Medical, INC. | $153.47 | 2023-2024 | Luna |
| Eisai INC. | $148.16 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $144.79 | 2021-2023 | |
| Amgen INC. | $131.61 | 2021 | |
| Lilly USA, LLC | $118.81 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $99.98 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.75 | 2021 | |
| Avadel Cns Pharmaceuticals, LLC | $71.00 | 2023-2024 | Lumryz |
| Arbor Pharmaceuticals, INC. | $59.11 | 2021 | |
| Idorsia Pharmaceuticals US INC | $55.40 | 2022-2023 | Quviviq |
| Itamar Medical INC | $49.61 | 2021-2023 | Watchpatone |
| Abbvie INC. | $49.31 | 2021 | |
| Ibsa Pharma INC. | $46.50 | 2021 | |
| Amarin Pharma, INC. | $37.26 | 2021 | |
| Bausch Health US, LLC | $18.33 | 2022 | |
| Dexcom, INC. | $16.25 | 2021 | |
| Grt US Holding, INC. | $14.03 | 2021 | |
| Radius Health, INC. | $13.34 | 2021 | |
| Recordati_rare_diseases_inc. | $12.79 | 2021 | |
| Esperion Therapeutics, INC. | $11.29 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnnie Westerfield listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.